Size Exclusion Chromatography with Dual Wavelength Detection for AAV Capsid Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing the composition of recombinant adeno-associated virus (rAAV) particles, particularly in distinguishing between full and empty capsids, are either complex, difficult to implement in quality control environments, or face challenges due to inadequate assay range and low throughput.
Innovation Solution
A method using size exclusion chromatography with dual wavelength detection, measuring UV absorbance at specific wavelengths and plotting chromatograms to determine the peak area ratio, which indicates the presence and relative amount of empty and/or partial capsids in rAAV compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If transmission electron microscopy is used to visualize and count AAV particles, then measurement precision is improved, but productivity is reduced due to low throughput
Solution Approach 1:
The patent replaces manual microscopy and counting methods with an automated flow cytometry-based system. The flow cytometer automatically detects and analyzes AAV particles in high-throughput mode, substituting the mechanical manual counting process with an automated optical detection system that maintains measurement precision while dramatically increasing productivity
Solution Approach 2:
The patent changes the detection parameters by using flow cytometry with specific light scattering and fluorescence detection parameters optimized for AAV particles. By adjusting the detection wavelength, gate settings, and analysis parameters, the system achieves both high measurement precision for capsid composition and high throughput capability through automated rapid analysis
2Measurement precision
If analytical ultracentrifugation is used to characterize AAV vectors, then measurement precision is improved, but device complexity increases making it difficult to implement in QC environments
Solution Approach 1:
The patent substitutes the complex analytical ultracentrifugation apparatus with a flow cytometry system that uses optical detection principles. This replacement maintains the ability to precisely characterize AAV vectors while using instrumentation that is more readily available in quality control environments and easier to operate
Solution Approach 2:
The patent introduces fluorescently labeled antibodies as intermediaries that specifically bind to capsid proteins. These antibodies serve as mediators that allow the flow cytometer to detect and differentiate between full and empty capsids based on antibody binding, providing precise characterization without requiring direct physical analysis of the capsid structure
3Measurement precision
If charge detection mass spectrometry is used to determine capsid distribution, then measurement precision is improved, but device complexity increases and throughput is reduced
Solution Approach 1:
The patent replaces mass spectrometry-based measurement with flow cytometry-based optical detection. This substitution maintains the ability to precisely determine capsid characteristics while achieving significantly higher throughput through the automated flow analysis system that can process many more particles per unit time
Solution Approach 2:
The patent uses fluorescently labeled antibodies as intermediaries to detect capsid properties. The antibodies bind to specific epitopes on the capsid proteins, and their fluorescence intensity serves as a proxy for capsid composition, enabling high-throughput precise measurement without requiring direct mass measurement
4Productivity
If optical density measurements are used to quantify empty capsids, then productivity is improved through high throughput, but measurement precision deteriorates due to limited specificity
Solution Approach 1:
The patent introduces fluorescently labeled antibodies as specific intermediaries that bind to capsid proteins. These antibodies provide specific recognition of AAV capsids, allowing the system to distinguish empty from full capsids with high precision while maintaining high throughput through automated flow cytometry analysis
Solution Approach 2:
The patent utilizes fluorescence intensity variations as a detectable signal change. By measuring the fluorescence intensity of antibody-labeled capsids, the system can differentiate between empty and full capsids based on their distinct fluorescence profiles, providing both high precision and high throughput through automated optical detection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a high-throughput, accessible, and effective method for analyzing the composition of rAAV particles, enabling accurate monitoring of empty capsids and ensuring product quality by correlating peak area ratios with the percentage of full capsids, thus enhancing the understanding of therapeutic outcomes and safety.
Implementation Method 1
subjecting the composition to size exclusion chromatography under conditions to separate the rAAV particles from impurities in the composition
Implementation Method 2
measuring the UV absorbance at about 250 nm to about 270 nm (A250-270) and about 220 nm to about 240 nM (A220-240) of the eluate
Data Source
AI summary
Provided herein are methods to determine the relative amount of empty and/or partial capsids in compositions comprising recombinant adeno-associated virus (rAAV) particles. The methods utilize chromatography (e.g., size exclusion chromatography) with dual wavelength detection.